Skip to main content
. 2022 Jun 17;113(8):2763–2777. doi: 10.1111/cas.15427

FIGURE 5.

FIGURE 5

Clinical utility of comprehensive genomic profiling in hematological malignancies. Proportion of patients harboring at least one somatic alteration with indicated clinical evidence level according to the Japanese Society of Hematology Genome Guideline in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL), B‐cell non‐Hodgkin lymphoma (B‐NHL), T/natural killer‐cell non‐Hodgkin lymphoma (T/NK‐NHL), and multiple myeloma (MM), and for all patients